Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 16, 2015 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Receives Notice of Allowance for Additional U.S. Patent for RHB-105 H. pylori Bacterial Infection Treatment

The U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a new formulation patent application covering RHB-105 H. pylori bacterial infection treatment, to expire no...
March 31, 2015 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Acquires Phase II First-in-Class Oral Small Molecule SK2 Inhibitor From Apogee Biotech

ABC294640 is a proprietary, first-in-class, new chemical entity (NCE) sphingosine kinase-2 (SK2) inhibitor, administered orally, which has successfully completed numerous pre-clinical studies and...
March 23, 2015 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma to Present at the 3rd Annual Autoimmune & Inflammation Leaders' Forum 2015

TEL-AVIV, Israel, March 23, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an Israeli biopharmaceutical company primarily focused on late clinical-stage,...
March 03, 2015 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma to Present at Bio-Europe Spring 2015 International Partnering Conference

TEL-AVIV, Israel, March 3, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...
March 03, 2015 06:05 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma to Present at the 27th Annual ROTH Conference

TEL-AVIV, Israel, March 3, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...
March 02, 2015 07:00 ET | Source: RedHill Biopharma Ltd.

Positive Bioavailability Studies of RedHill's BEKINDA(TM) to be Presented at the 2015 American Society for Clinical Pharmacology and Therapeutics (ASCPT) Meeting

The results from two positive bioavailability studies, previously reported by the Company, demonstrate the safety and tolerability of BEKINDA™ and support the European marketing application...
February 26, 2015 07:50 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Reports 2014 Fourth Quarter and Year-End Financial Results

Key Highlights Include: Strong cash position of over $34 million, following completion of a $14.4 million U.S. public offering in February 2015 With three ongoing Phase III clinical...
February 19, 2015 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma to Host 2014 Fourth Quarter and Year-End Financial Results Conference Call on February 26, 2015

TEL-AVIV, Israel, Feb. 19, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...
February 18, 2015 09:56 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces Full Exercise of Underwriters' Over-Allotment Option

TEL-AVIV, Israel, Feb. 18, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...
February 13, 2015 10:18 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces Closing of Public Offering of Its American Depository Shares

TEL-AVIV, Israel, Feb. 13, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...